1. Stable urea isotopes can be used to study urea kinetics in humans. The use of stable urea isotopes for studying urea kinetic parameters in humans on a large scale is hampered by the high costs of the labelled material. We devised a urea dilution for measurement of the distribution volume, production rate and clearance of urea in healthy subjects and renal failure patients using the inexpensive single labelled [13C]urea isotope with subsequent analysis by headspace chromatography-isotope ratio MS (GC-IRMS) of the [13C]urea enrichment. 2. The method involves measurement of the molar percentage excess of [Wlurea in plasma samples taken over a 4 h period after an intravenous bolus injection of [13C]urea. During the sample processing procedure, the plasma samples together with calibration samples containing a known molar percentage excess of [13C]urea are acidified with phosphoric acid to remove endogenous COz, and are subsequently incubated with urease to convert the urea present in the plasma samples into COz. The 13C enrichment of the generated COz is analysed by means of GC-IRMS. This method allows measurement of the molar percentage excess of [13C]urea to an accuracy of 0.02%. 3 . Reproducibility studies showed that the sample processing procedure [within-run coefficient of variation (CV) <2.8% and between-run CV <8.8%] and the GC-IRMS analysis (within-day CV <1.3%
and between-day CV < 1.3%) could be repeated with good reproducibility.
4.
In clinical urea kinetic studies in a healthy subject and in a renal failure patient without residual renal function, reproducible values of the distribution volume, production rate and clearance of urea were determined using minimal amounts of [13C]urea (25-50 mg). 5. Because only low [13C]urea enrichments are needed in this urea dilution method using GC-IRMS analysis, the costs of urea kinetic studies are reduced considerably, especially in patients with renal failure.
INTRODUCTION
To assess the quality of the haemodialysis treatment of patients with chronic renal failure, kinetic modelling of urea is widely used. Clinically, the most relevant results from urea kinetic modelling are KIT/ ('dose of dialysis') and protein catabolic rate (a measure of protein intake under stable conditions). An essential parameter to determine the protein catabolic rate is the urea distribution volume (UDV) [l] . The UDV, which is assumed to equal total body water [2] , comprises multiple compartments of the human body. The size of the UDV can be determined by kinetic modelling of urea during the haemodialysis treatment. However, it is difficult to obtain an accurate measurement of the UDV by single-pool urea kinetic modelling due to compartimentalization of urea. Therefore, complex multiplepool urea kinetic models have been proposed for studying urea kinetics during haemodialysis [3] .
The reference method for the determination of the UDV is the dilution of exogenous urea. Natural urea and various urea isotopes have been used in these dilution studies [4-81. In a previous paper we have described a urea dilution method using the triple labelled [l3Cl5N2] urea isotope and gas chromatography-MS (GC-MS) analysis for study-ing urea kinetics in normal humans [9] . In patients with chronic renal failure, however, the use of the dilution method using the [13C15Nz] urea isotope is limited, since more of the costly labelled material is needed. The blood urea concentration in these uraemic patients is about 4-6-fold higher than that in healthy subjects. Consequently, considerably more [13C15Nz] urea is required to achieve detectable enrichments. To reduce the costs of urea isotope dilution studies in uraemic patients, it is worthwhile investigating dilution methods that require less expensive urea isotopes and low isotope enrichments.
In this paper we describe a urea dilution method using the inexpensive single labelled [13C]urea isotope and headspace gas chromatography-isotope ratio MS (GC-IRMS) analysis for determining [13C]urea enrichments. We have succeeded in devising a urea dilution method in which minimal amounts of the [13C]urea isotope suffice to determine urea kinetic parameters in normal subjects and in uraemic patients.
MATERIALS AND METHODS

Chemicals
[13C]Urea (99% 13C) was obtained from Campro Scientific, Veenendaal, The Netherlands, and 85% phosphoric acid (H3P04) and amylalcohol from E. Merck Nederland B.V., Amsterdam, the Netherlands. Urease (cat. nr. U 4002, 80.000units/g) was purchased from Sigma Chemical Company, St Louis, MO, U.S.A. and stored at 0-5°C until use.
Standard solutions
[13C]Ureu. A stock solution of [13C]urea was prepared by dissolving approximately 50mg of [13C]urea in 100ml of distilled water and this solution was then diluted 50-fold. Aliquots (2.5 ml) of this stock solution were stored frozen at -20°C. Each time GC-IRMS analyses were performed, a 10-fold (healthy person) or 5-fold diluted (renal failure patient) working solution was made from the stored aliquots using 0.9% NaCl as diluent.
Urease. A stock solution of urease containing approximately 3000 units/ml was prepared by disolving 0.26 g of urease in 3.5 ml of H2O and 3.5 ml of glycerol, and was stored at 4 -6°C. This solution was stable for 6 months. Each time GC-IRMS analyses were performed a working solution (30 unitsfl) was made by diluting the stock solution 100-fold with a 10 gil EDTA.Na2 buffer solution (pH 6.9). The EDTA.Na2 buffer solution was stable for 6 months.
Headspace GC-IRMS
A Delta-S GC-IRMS combination (Finnigan MAT, Bremen, Germany), equipped with a Varian 3400 GC, was used to determine 13C02/12C02 ratios in the gas mixture present in the Vacutainer tubes after conversion of the [13C]urea/[12C]urea mixtures by means of urease (see analytical procedures below). Gas mixtures were injected on a 25 m Poraplot Q capillary column (Chrompack, Middelburg, The Netherlands), internal diameter 0.32 mm, with helium as the carrier gas. The injection temperature was 120"C, oven temperature 70°C, split ratio 1 : l O . 13C02/12C02 ratios were determined as delta (6) value against the international PDB-standard carbon dioxide [lo] . An increase in 6 value of 1000 corresponds to an increase of 1% in the 13c02/12c02 ratio [ = molar percentage excess (MPE) of 13CO~]. Reproducibility tests were performed using these calibration mixtures.
In the clinical urea kinetic studies, a calibration line was constructed for each subject individually from plasma samples (0.5 ml) drawn from the studied subject immediately before administration of labelled urea. To cover the range up to 0. 
Analytical procedures
Sample processing for GC-IRMS analysis. Appropriate amounts of HzO were added to the calibration mixtures and to the plasma samples (0.5 ml) collected during the urea kinetic studies in order to bring all solutions to the same volume (2.0 ml). Calibration mixtures and patient plasma samples were then processed in one run using the the same procedure.
The samples were placed in aluminium holders in a dry block heater, set at 37°C. To facilitate the removal of C02 originating from HC03-present in the mixtures, the samples were acidified to pH 2.0-3.0 by adding 25 pl of 1 mol/l H3P04 and mixed. A vigorous stream of NZ gas was passed from the bottom through the contents of each tube. To prevent foaming, 125 pl of amylalcohol was added to all samples. After 30min the endogenous COz present in the samples was maximally expelled and the pH was about 6.5. The tubes were then closed rapidly with the rubber stoppers supplied, taking care no air was enclosed. Then 1 ml of urease working solution (30 units/l, pH 6.9) was added by injection through the stopper and the contents of the tubes was again thoroughly mixed. During an incubation period of 15 min at 37°C the urea in the solution was converted into COz and NH3. To liberate the generated C02 from the solution, the pH was adjusted to less than 2 by adding 75 pl of 1 molj H3P04 through the stopper. The stoppered tubes were then rotated for 30min on an orbital shaker. The gas mixtures remained stable for at least 2 weeks at 2-6°C.
GC-IRMS analysis. Analysis of the 13C enrichment of the generated COz was performed within 2 weeks after sample processing. Samples (100 pl) of the gas mixture present in the VacutaineP tubes were injected manually into the GC-IRMS combination by means of a gas-tight syringe. Samples were injected in order of increasing enrichment to minimize memory effects.
Analysis of plasma urea concentration. Urea concentrations of the separate plasma samples from the urea kinetic studies were determined by means of a Kodak Ektachem 500 analyser and converted into plasma water concentration by dividing the measured values by 0.93 [ll] .
Reproducibility studies
Sample processing procedure. The within-run reproducibility of the sample processing procedure was determined by measurement of the 6 values of eight series of calibration mixtures that were prepared, processed and analysed in one run on the same day. The between-run reproducibility was determined by measuring the 6 values of eight series of calibration mixtures that were prepared, processed and analysed on separate days over a period of 1 year. Reproducibility of the sample processing procedure was expressed as the coefficient of variation (CV=mean/SD) of the 6 values of the eight calibration series. In addition, the slope of the calibration line was determined and the within-run and between-run reproducibility of the slope was calculated.
GC-IRMS analysis procedure. Reproducibility of the GC-IRMS analysis itself was determined according to the following procedure: eight series of calibration mixtures were prepared and processed in one run on the same day. The calibration series were analysed in random order. To determine the within-day reproducibility of the GC-IRMS analysis procedure, the 6 values of the eight calibration mixtures were measured three times on the same day. The CV values of each series of the eight calibration mixtures were calculated and averaged to obtain the mean within-day reproducibility. To determine the between-day reproducibility, the 6 values of the calibration mixtures were measured again on three separate days within 1 week. Again the corresponding CV values were calculated and averaged to obtain the mean between-day reproducibility of the GC-IRMS analysis procedure.
Clinical urea kinetic study. To evaluate the repeatability of the urea kinetic parameters in man, four urea kinetic studies were performed in a healthy volunteer within 4 months.
Clinical urea kinetic studies
The clinical studies were carried out after approval of the Medical Ethics Committee of the University of Groningen and the informed consent of participants was obtained.
Subjects. Urea kinetics were determined in two male subjects: one healthy volunteer (age, 57 years; height, 182 cm; body weight, 86 kg) and one stable patient without residual renal function on thrice weekly haemodialysis (age, 38 years; height, 177 cm; body weight, 71.5 kg). The patient with renal failure was studied during an interdialytic period.
Urea kinetics. Both subjects were studied in the morning after a 12 h overnight fast, and remained fasting during the course of the study. The subjects received an intravenous injection of [13C]urea dissolved in 24ml of 0.9% NaCl solution in 45 s through a heparin lock. The healthy volunteer received a dose of 24 mg ( = 0.39 mmol) and the renal failure patient 48 mg ( = 0.79 mmol) of [13C]urea. The solution was prepared in and dispensed from 30 ml syringes under sterile conditions on the day of the study. Blood samples were drawn in 4 ml VacutaineP tubes containing lithium-heparin through a heparin lock in the opposite arm just before the injection (t = 0) and at 2, 5, 10, 15 and 30min, and every 30min until 4 h after injection. Plasma was separated from the red blood cells and aliquots of 0.5 ml were pipetted into sterile Vacutainef tubes without additive and stored at -20°C until GC-IRMS analysis. In addition, separate 400pl aliquots were pipetted and stored for the analysis of plasma urea concentration. using the slope and intercept of the calibration lines that were prepared from their own plasma samples obtained before the injection of [13C]urea. In the calculations of the urea kinetic parameters it is assumed that the kinetic handling of the labelled [13C]urea and unlabelled [12C] urea is equal. After the injected labelled urea is completely distributed within the body, the change over time of the natural logarithmic value of the ratio labelled/unlabelled urea follows a straight line with a negative slope. If UDV, the production rate of urea and the plasma urea concentration are assumed to be constant, this change is defined by eqn. (1):
In Rt = In Ro-t k,
(1) in which Rt represents the ratio labelled/unlabelled urea at time t, Ro is the ratio at t = 0, and k, is the production constant of urea (the slope of the regression line of the natural logarithmic values of R plotted against time) [5] . The UDV can be calculated from the intercept of the extrapolated regression line, representing the apparent ratio Ro at t = 0, according to eqn. (2):
The production rate of urea (Gu) is calculated from UDV, k, and the plasma urea concentration (U) according to eqn. (3) [5] : Reproducibility is expressed as CV. Regression analysis was performed using least-squares linearregression analysis.
RESULTS
Calibration lines
We found an excellent linear correlation 
Reproducibility studies
The within-run reproducibility (CV 0.6-2.8%) of the sample processing procedure was good and the between-run reproducibility (CV 1.8-8.8%) was acceptable ( Table 1 ). The within-day (CV 0.4-1.3%) and between-day (CV 0.4-1.3%) reproducibility of the GC-IRMS analysis was even better. The variability of the processing procedure and GC-IRMS analysis tended to be somewhat higher in the samples containing low [l3C]urea enrichments.
The variability of the processing and analytical procedures had only a small effect on the reproducibility of the slope of the calibration curves that were prepared, processed and analysed on the same day (within-run CV 0.6%) and on different days within one year (between-run CV 1.8%). The UDV divided by the body weight of the healthy volunteer was higher (65% of body weight)
3
-m -1. Oi than that of the renal failure patient (52% of body weight) ( Table 2 ). The reproducibility of the repeated UDV measurements was acceptable with a CV value of 3.5%. The production constant of urea (kp) was determined from the slope of the regression line of the MPE of [13C]urea values after 90min and GU was calculated according to eqn. (3). The production rate of urea was about the same for both subjects, but varied considerably between the repeated measurements in the healthy volunteer. The decay curves of the natural logarithmic values of the [I3C]urea plasma water concentrations in the volunteer and renal failure patient are shown in Fig.  2 (lower panel) . The elimination constant (ke) of urea was determined from the slope of the regression line of [13C]urea concentration values after 90min. The ke of urea was about 6-fold higher in the healthy volunteer (0.0674 h-l ) than in the renal failure patient (0.0120 h-l). Calculated urea clearance in the healthy volunteer was also higher than in the renal failure patient. However, [13C]urea clearance in the renal failure patient was still 7.4 ml/min, despite the fact that the patient had no residual renal function.
DISCUSSION
We have described a urea dilution technique using the stable urea isotope [13C]urea and headspace GC-IRMS analysis for measuring kinetic parameters of urea in healthy subjects and chronic haemodialysis patients. The use of the relatively inexpensive [13C]urea isotope in the dilution method described in this paper reduces the high costs that are associated with the previously reported urea isotope dilution methods [6-91. We have shown that there is an excellent linear correlation between the MPE of [13C]urea and the 6 values measured by GC-IRMS and that this correlation could be reproduced accurately. Of interest is the measured 6 value for a given MPE of [13C]urea in the calibration mixtures (Fig. 1) . Since an increase of 16 is defined to be equivalent to 0.001 (5) the determination of the natural plasma urea concentration is precise and accurate. In practice, however, the 6 values of the calibration mixtures prepared from pooled plasma were lower than the expected values, resulting in a calibration line with a slope of about 9156 per MPE of [13C]urea. The recovery of 92% probably demonstrates that not all the conditions required for obtaining the maximal 6 values were fulfilled. Two of the conditions mentioned are most likely responsible for the lower 6 values. One reason may be an incorrect determination of the plasma urea concentration by the Kodak analyser. The urea concentration of the pooled plasma was determined only once. The recovery of the calibration mixtures would have been 100% if the true urea concentration of the pooled plasma was only 8% lower than the urea concentration determined by the analyser.
The main reason, however, is probably the presence of residual endogenous COz that is not completely expelled from the samples. Since the [13C] enrichment of endogenous COz is zero, residual COzwill lower the [13C] enrichment of the COZ derived from the [13C]urea in the enriched plasma samples. Bennett et al. [12] used a similar procedure to convert urea into COz in a study on the incorporation of [13C]bicarbonate into urea in vivo [12] . The authors described a sample processing procedure in which a larger quantity of H3P04 is used to liberate natural plasma COz. To improve the 6 values we also used a larger quantity of H3P04 and increased the duration of COZ removal, but these alterations in the sample processing procedure did not have any beneficial effects. If a larger quantity of H3P04 is used, the solution has to be adjusted to pH 7.0 using an alkaline solution. Bennett et al. [12] used NaOH for this adjustment, but this may increase the risk of contaminating the COz-free solution with natural COz that may be dissolved in the NaOH solution, since COz is easily trapped by this alkaline solution. We only added approximately twice the required number of hydrogen ions to liberate all endogenous COz. In this way, no additional NaOH was needed, minimizing contamination with COz. Because we were not able to improve the recovery of the [13C]urea enrichments in the calibration mixtures, the endogenous COz was probably expelled maximally. This does not mean that endogenous COz was expelled completely. Because the endogenous plasma C02 and urea concentrations can differ significantly between subjects, and especially between healthy persons and renal failure patients, we decided to prepare a calibration line for each individual separately from plasma samples drawn from the studied subject just before [13C]urea injection. By using individual calibration lines, differences in the experimental conditions between the calibration mixtures and plasma samples were minimized, including the effect of residual endogenous coz.
After intravenous injection, [13C]urea was completely distributed over the UDV in approximately 90 min in both the healthy subject and renal failure patient (Fig. 2.) . Although it cannot be concluded from this small clinical study that the duration of the equilibration period is the same in healthy subjects and patients with chronic renal failure, our results are in accordance with the study by Pearson et al. [8] , who concluded that end-stage renal failure patients do not have two-compartment characteristics that are substantially different from normal subjects. [13] calculated a larger range (0-20%) of excess urea loss in normal subjects. In a study in four normal subjects by Varcoe et al. [6] excess loss of urea isotope was less than 2%. Thus the error that is made in the calculation of UDV due to excess loss of [13C]urea during the equilibration period appears to be very small.
The values of UDV that were measured in the two subjects studied are comparable with the values found in other urea dilution studies using intravenously injected urea isotopes [5-91. Watson et al. [14] analysed multiple reports on dilution measurements of total body water, which is assumed to approximately equal the UDV, and showed that total body water can vary widely from 38 to 73% of body weight between individual males. We have previously determined UDV by urea kinetic modelling during haemodialysis in the renal failure patient [15] . By relating the total amount of urea excreted into the dialysate to the decrease in plasma urea concentration during the dialysis UDV can be calculated. UDV determined by urea kinetic modelling during haemodialysis was 35.3 litres (50% of body weight), whereas it was 37.3 litres (52% of body weight) by [13C]urea dilution method. This suggests that, at least in this patient, the [13C]urea dilution method and urea kinetic modelling during haemodialysis yield comparable results.
The production rate of urea (Gu) was comparable with the production rates reported in the literature and was about the same for the healthy subject and the renal failure patient [5, 71 . The urea production rate varied considerably among the repeated studies in the healthy subject, although the subject was studied after an overnight fast and remained fasting during the studies. Since we did not prescribe a particular protein diet to the volunteer, the variability in GU may originate from differences in protein intake during the days before the studies. When a subject switches from a normal diet to a low-protein diet it takes several days until a new equilibrium with a decreased level of nitrogen excretion is established, indicating that adaptation of the urea production rate to changes in protein intake is not instantaneous [16] .
Not surprisingly, the clearance of urea in the healthy volunteer was much higher than that in the renal failure patient. Although the patient had no residual renal function urea clearance was 7.4 ml/min. Probably, the extrarenal [13C]urea clearance in renal failure patients originates from hydrolysis of urea in the gastro-intestinal tract by urease-containing bacteria [13] . The measured urea clearance in our patient was somewhat lower than the clearance values in patients with end-stage renal failure that have been reported by Pearson et al. [8] . Those authors found urea clearance values between 13.8 and 43.6mVmin. However, some of these patients had various degrees of residual renal function.
Our principal interest was to develop a urea dilution method that is as precise as the earlier decribed method using [13C15Nz]urea [9] but less costly. Since the price of single labelled [13C]urea isotope is only one fifth of that of [13C15Nz]urea, and since we were able to reduce the required amount of labelled material 4-fold due to the low enrichments required in GC-IRMS analysis, the total cost of the labelled material was reduced by a factor of 20.
In summary, we have described a urea dilution technique using the stable urea isotope [13C]urea and headspace GC-IRMS analysis for measuring urea kinetic in healthy human subjects and patients without residual renal function. Very low enrichments of [13C]urea were sufficient to measure the distribution volume, production rate and clearance of urea in a healthy subject and a patient with chronic renal failure with good reproducibility. The low cost of this [13C]urea dilution method provides the possibility of studying urea kinetics on a larger scale, especially in patients with end-stage renal failure.
